Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Temporal priority of lifetime alcohol use disorders and comorbid psychiatric disorders in adults: Results from a population-based nationwide survey in Korea.

Journal of affective disorders·2023

Same author

A Personalized Cancer Vaccine that Induces Synergistic Innate and Adaptive Immune Responses.

Advanced materials (Deerfield Beach, Fla.)·2023

Same author

Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study).

Annals of dermatology·2023

Same author

Prescription Patterns of Topical Medications in Patients with Atopic Dermatitis: An Investigative Review Using Big Data from the National Health Insurance Corporation.

Annals of dermatology·2023

Same author

Giant Cellulitis-like Sweet Syndrome Following Varicose Vein Surgery: A Rare Variant of Sweet Syndrome Mimicking Cellulitis.

Annals of dermatology·2023

Same author

Prevalence of Mental Disorders and Associated Factors in Korean Adults: National Mental Health Survey of Korea 2021.

Psychiatry investigation·2023

Search research articles

Related Experiment Video

Updated: Mar 27, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Therapeutic angiogenesis using tumor cell-conditioned medium.

Hyeon-Ki Jang¹, Byung-Soo Kim^1,2,3, Jin Han²

¹Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 151-744, Republic of Korea.

Biotechnology Progress

|January 11, 2016

Summary

Tumor cell-conditioned medium (CM) effectively promotes therapeutic angiogenesis. This study demonstrates tumor cell CM

Keywords:

ischemia mesenchymal stem cell therapeutic angiogenesis tumor cell-conditioned medium

More Related Videos

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Related Experiment Videos

Last Updated: Mar 27, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Area of Science:

Biotechnology
Regenerative Medicine
Vascular Biology

Background:

Stem cell-conditioned medium (CM) is a potential therapy for ischemic diseases due to its angiogenic factors.
Tumor cells also secrete angiogenic factors, presenting an alternative source for CM production.

Purpose of the Study:

To evaluate tumor cells as a source for CM in therapeutic angiogenesis.
To demonstrate the therapeutic efficacy of tumor cell CM in a mouse hindlimb ischemia model.

Main Methods:

Compared CM from human fibrosarcoma HT1080 cells with CM from human bone marrow-derived mesenchymal stem cells (MSCs).
Assessed angiogenic factor concentrations and in vitro human umbilical vein endothelial cell (HUVEC) proliferation.
Evaluated in vivo therapeutic efficacy by injecting HT1080 CM into mouse ischemic limbs.

Main Results:

HT1080 CM had higher angiogenic factor concentrations than MSC CM due to faster cell growth.
Both HT1080 CM and MSC CM induced similar HUVEC proliferation in vitro on a per-cell basis.
HT1080 CM injection significantly improved capillary density and blood perfusion in mouse ischemic limbs.

Conclusions:

Tumor cell CM shows therapeutic potential for angiogenesis and ischemic diseases.
Tumor cell lines offer a more efficient source for CM production compared to MSCs due to faster growth and unlimited lifespan.
Tumor cell CM represents a promising alternative for therapeutic angiogenesis.